Related Experiment Video
Updated: Jul 2, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Microglial cGAS drives neuroinflammation in the MPTP mouse models of Parkinson's disease
Chunmei Ma1, Ying Liu2, Sheng Li1,3
1Department of Immunology, State Key Laboratory of Reproductive Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Gusu School, Nanjing Medical University, Nanjing, China.
Background:
Neuroinflammation has been widely accepted as a cause of the degenerative process. Increasing interest has been devoted to developing intervening therapeutics for preventing neuroinflammation in Parkinson's disease (PD). It is well known that virus infections, including DNA viruses, are associated with an increased risk of PD. In addition, damaged or dying dopaminergic neurons can release dsDNA during PD progression. However, the role of cGAS, a cytosolic dsDNA sensor, in PD progression remains unclear.
Methods:
Adult male wild-type mice and age-matched male cGAS knockout (cGas-/- ) mice were treated with MPTP to induce neurotoxic PD model, and then behavioral tests, immunohistochemistry, and ELISA were conducted to compare disease phenotype. Chimeric mice were reconstituted to explore the effects of cGAS deficiency in peripheral immune cells or CNS resident cells on MPTP-induced toxicity. RNA sequencing was used to dissect the mechanistic role of microglial cGAS in MPTP-induced toxicity. cGAS inhibitor administration was conducted to study whether GAS may serve as a therapeutic target.
Results:
We observed that the cGAS-STING pathway was activated during neuroinflammation in MPTP mouse models of PD. cGAS deficiency in microglia, but not peripheral immune cells, controlled neuroinflammation and neurotoxicity induced by MPTP. Mechanistically, microglial cGAS ablation alleviated the neuronal dysfunction and inflammatory response in astrocytes and microglia by inhibiting antiviral inflammatory signaling. Additionally, the administration of cGAS inhibitors conferred the mice neuroprotection during MPTP exposure.
Conclusions:
Collectively, these findings demonstrate microglial cGAS promote neuroinflammation and neurodegeneration during the progression of MPTP-induced PD mouse models and suggest cGAS may serve as a therapeutic target for PD patients.
Limitations Of The Study:
Although we demonstrated that cGAS promotes the progression of MPTP-induced PD, this study has limitations. We identified that cGAS in microglia accelerate disease progression of PD by using bone marrow chimeric experiments and analyzing cGAS expression in CNS cells, but evidence would be more straightforward if conditional knockout mice were used. This study contributed to the knowledge of the role of the cGAS pathway in PD pathogenesis; nevertheless, trying more PD animal models in the future will help us to understand the disease progression deeper and explore possible treatments.
Insights
The cyclic GMP-AMP synthase (cGAS) pathway in microglia drives neuroinflammation and neurodegeneration in Parkinson's disease (PD) models. Inhibiting cGAS offers neuroprotection, suggesting it as a potential therapeutic target for PD.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Neuroinflammation is a key factor in neurodegenerative diseases like Parkinson's disease (PD).
- Virus infections and released double-stranded DNA (dsDNA) are linked to increased PD risk.
- The role of the cytosolic dsDNA sensor, cGAS (cyclic GMP-AMP synthase), in PD progression is not fully understood.
Purpose of the Study:
- To investigate the role of the cGAS-STING pathway in MPTP-induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
- To determine whether cGAS deficiency in specific cell types (microglia vs. peripheral immune cells) impacts PD pathogenesis.
- To evaluate cGAS as a potential therapeutic target for Parkinson's disease.
Main Methods:
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was used to induce a neurotoxic PD model in wild-type and cGAS knockout mice.
- Behavioral tests, immunohistochemistry, and ELISA were performed to assess disease phenotypes.
- Chimeric mice and RNA sequencing were utilized to elucidate the mechanistic role of microglial cGAS, and cGAS inhibitors were tested for therapeutic effects.
Main Results:
- The cGAS-STING pathway was activated during MPTP-induced neuroinflammation in PD mouse models.
- cGAS deficiency specifically in microglia, not peripheral immune cells, mitigated neuroinflammation and neurotoxicity.
- Microglial cGAS ablation reduced neuronal dysfunction and inflammatory responses by inhibiting antiviral signaling, and cGAS inhibitors provided neuroprotection.
Conclusions:
- Microglial cGAS promotes neuroinflammation and neurodegeneration in MPTP-induced PD mouse models.
- These findings highlight cGAS as a potential therapeutic target for Parkinson's disease.
- Targeting the cGAS pathway may offer a novel strategy for treating PD.
